Jeffrey Crawford
Jeffrey Crawford

Jeffrey Crawford

George Barth Geller Distinguished Professor for Research in Cancer

Overview

1. Lung cancer/new treatment approaches.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care

Accomplishments

1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.

Positions

George Barth Geller Distinguished Professor for Research in Cancer in the School of Medicine

2005 School of Medicine

Professor of Medicine in the School of Medicine

1997 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

1974 School of Medicine

Education

M.D. 1974

1974 Ohio State University

Publications, Grants & Awards

DCI Centers, Cancer Types & Labs

Offices & Contact

25177 Morris Bldg
Durham, NC
27710
Duke Box 3476
Durham, NC
27710